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Dear Editor,
We have read the recent results from the study on
osteoporosis prevention in chronic (>90 days) glucocorti-
coid users by Feldstein et al. [1] and have three comments.
1. We believe that any apparent under-treatment may be
partly due to the fact that the data analysed were collected
from January 2000–December 2001. The American
College of Rheumatology (ACR) guidelines for prevention
of glucocorticoid-induced osteoporosis were published in
July 2001 and recommended that osteoporosis prevention
should be considered in those patients treated on ≥5 mg of
prednisolone per day [3]. The guidelines available before
this suggested that patients should be considered for
osteoporosis prevention if the dose was greater than 7.5 mg
per day, and the patients were treated for >6 months with
the glucocorticoid [4]. We believe to be fair to the
prescribers and other primary-care clinicians it should be
noted that at the time that these data were collected most
would only be aware that patients treated with ≥7.5 mg
prednisolone should be considered for osteoporosis
prevention.
2. There was no information on calcium or vitamin D
(activated or non-activated) use. Were these medications/
supplements excluded/not considered or unavailable? We
believe these are important to mention because they were
listed in the 1996 and 2001 ACR guidelines. In addition,
clinical trials with bisphosphonates have included calcium/
vitamin D in their protocol.
3. The authors note that their population had a high mean
prednisone dose of 20mg/day. We believe that this
unusually high dose of corticosteroid is due partly to
their methods in calculating the “average” dose. The mean
dose was obtained by using supplied quantities and not the
actual dose. The authors included all medications dis-
pensed including those during hospitalisation, which
probably accounts for the high mean dose. For example,
asthmatic/COPD patients (or other patients with sliding
scales) with frequent admissions to hospital are likely to
receive short courses of high-dose corticosteroid therapy in
hospital, which will undoubtedly increase the mean dose. It
would be interesting to know if these doses were excluded,
and what the median (and range) dose of corticosteroid
therapy was, i.e. what is the usual maintenance dose of
corticosteroid? This may be an important consideration for
prescribers when considering osteoporosis prevention
because the correlation between daily dose and fracture is
stronger than for cumulative dose [2]. Having said that, we
don’t expect the overall results from this study (i.e.,
underuse of osteoporosis prevention) would change
significantly.
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